EN DE
STOCK COMPARISON

Icecure Medical vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Icecure Medical (ICCM) and Abbott Laboratories (ABT) compare, as of Aug 18, 2026.

As of Aug 18, 2026, Fair Value Calculator sees Icecure Medical as the less overvalued of the two: Icecure Medical trades at $2.82 versus a fair value of $1.93 (-32%), while Abbott Laboratories trades at $110 versus $74.79 (-32%).
Icecure Medical
ICCM · USD · Health Care
-32%
upside to fair value
overvalued
Price$2.82
Fair Value$1.93
Quality37/100
Abbott Laboratories
ABT · USD · Health Care
-32%
upside to fair value
overvalued
Price$110
Fair Value$74.79
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Icecure MedicalAbbott Laboratories
Valuation
P/E (TTM)27.7×
2.62×P/S (TTM)3.89×
1.14×P/B3.36×
EV/EBITDA15.1×
PEG1.47×
Dividend yield2.7%
Profitability
0%Net margin14%
Operating margin13%
-228%Return on equity12%
-74%Return on assets6%
Growth
73%Revenue growth (YoY)8%
3.1%Avg. growth/yr (3Y)0.5%
-3.7%Avg. growth/yr (5Y)5.1%
Balance & size
Debt / equity0.19×
$10MMarket cap$175B
weakGrowth qualityhealthy

Even match: 4 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Icecure Medicalof which business quality 37 · market factors 15 Abbott Laboratoriesof which business quality 66 · market factors 54
ProfitabilityMargins and returns on capital today
5
50
Quality GrowthAre margins and returns improving?
53
47
CashflowEarnings quality: real cash, not paper profit
10
71
Fin. StrengthBalance sheet, leverage, solvency risk
75
80
InvestmentDisciplined investing over empire-building
100
65
Low VolatilityCalm price path (market factor)
50
83
MomentumPrice trend over the last 3–12 months (market factor)
0
45
52W MomentumDistance to the 52-week high (market factor)
1
37
Net IssuanceBuybacks instead of dilution
0
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Icecure Medical

Asset-Based$1.77

1 of 1 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Icecure Medical
Bear $1.28Fair Value $1.93Bull $2.41
$2.82 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$110 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Icecure Medical · Health Care

Quality score37 · bottom 25%
Fair value upside-32% · below median

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-32% · below median

Bottom line

As of Aug 18, 2026, Fair Value Calculator sees Icecure Medical as the less overvalued of the two: Icecure Medical trades at $2.82 versus a fair value of $1.93 (-32%), while Abbott Laboratories trades at $110 versus $74.79 (-32%).

Abbott Laboratories has the higher quality score (67/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.